SEC Filing Summary: Inmune Bio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Inmune Bio, Inc. on November 4, 2022, covering the date of the earliest event reported on November 2, 2022. The Company is an emerging growth company incorporated in Nevada with principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely as a vehicle to disclose the occurrence of an earnings call and to attach the call script as an exhibit.
Material Changes
No material changes to financial position or operations are detailed within the text of this specific Form 8-K. The report references an earnings call held on November 2, 2022, but does not summarize the financial results or operational updates discussed during that call.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies. The primary purpose of this document is to satisfy the disclosure requirement for the earnings call script, which is attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Script for earnings call) for detailed financial results and management commentary not included in this summary.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the trading symbol "INMB" on The NASDAQ Stock Market LLC.
- Check subsequent filings (e.g., Form 10-Q or 10-K) for the actual financial data discussed in the referenced earnings call.